









Markets
/
Stocks
/
nasdaq-sprc
/

Scisparc Ltd

SPRC

4.770USD

+0.120+2.58%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

238.30KMarket Cap

LossP/E TTM



Scisparc Ltd

4.770

+0.120+2.58%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

131 / 175

Overall Ranking

570 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.31M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 142.44.

Fairly Valued

The company’s latest PE is -2.87, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.89K shares, decreasing 42.34% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 2.07K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.65.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Pharmaceuticals industry's average is 7.84.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -2.80, which is -87.56% below the recent high of -0.35 and -113.55% above the recent low of -5.97.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 131/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.87, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 6.76 and the support level at 2.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.87

Change

0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.748

Neutral

RSI(14)

64.974

Neutral

STOCH(KDJ)(9,3,3)

57.219

Buy

ATR(14)

0.620

High Vlolatility

CCI(14)

160.864

Buy

Williams %R

34.490

Buy

TRIX(12,20)

-2.560

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

3.506

Buy

MA10

2.710

Buy

MA20

2.947

Buy

MA50

4.896

Sell

MA100

2.924

Buy

MA200

1.661

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 1.10%, representing a quarter-over-quarter decrease of 2.33%. The largest institutional shareholder is James Simons, holding a total of 2.07K shares, representing 0.13% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

UBS Financial Services, Inc.

-100.00%

Yorkville Advisors Global, LP.

2.63K

Renaissance Technologies LLC

Star Investors

-100.00%

SBI Securities Co., Ltd.

14.00

+366.67%

Shrem (Itschak)

16.00

+128.57%

Rhumbline Advisers Ltd. Partnership

1.00

-99.39%

BofA Global Research (US)

2.00

-66.67%

Weiss (Amitay)

1.00

J.P. Morgan Securities LLC

-100.00%

Morgan Stanley & Co. LLC

-100.00%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.04, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.02. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.